Q-omics provides the consensus-scored GAPDHP24 profile across patient tissues and cancer cell-line models. GAPDHP24 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GAPDHP24 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, GAPDHP24 RNA expression shows 7,774 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, HNSC, and TGCT as cancer lineages where GAPDHP24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP24 survival associations across molecular data types. GAPDHP24 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP24 RNA expression–survival associations across cancer types. High GAPDHP24 expression shows unfavorable associations in STAD, BRCA, SKCM and ACC, but favorable associations in LUSC and COAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for GAPDHP24 RNA expression.
This table summarizes GAPDHP24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP24 shows higher tumor expression in HNSC, LUSC, LUAD, KIRC and LIHC. The HNSC box plot shows higher GAPDHP24 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .001).
This table shows molecular features associated with GAPDHP24 in patient tissues and cancer cell lines. In patient samples, GAPDHP24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
